| Primary |
| Rheumatoid Arthritis |
41.7% |
| Polyarthritis |
8.3% |
| Psoriasis |
8.3% |
| Acute Lymphocytic Leukaemia |
4.2% |
| Analgesic Therapy |
4.2% |
| Cardiac Failure |
4.2% |
| Chondrosarcoma |
4.2% |
| Diabetic Vascular Disorder |
4.2% |
| Hypersensitivity Vasculitis |
4.2% |
| Hypertension |
4.2% |
| Obesity |
4.2% |
| Thrombosis Prophylaxis |
4.2% |
| Type 1 Diabetes Mellitus |
4.2% |
|
| Thrombocytopenia |
25.0% |
| Choreoathetosis |
12.5% |
| Renal Cell Carcinoma |
12.5% |
| Saliva Altered |
12.5% |
| Septic Shock |
12.5% |
| Thrombosis |
12.5% |
| Urticaria |
12.5% |
|
| Secondary |
| Rheumatoid Arthritis |
39.5% |
| Product Used For Unknown Indication |
27.7% |
| Drug Use For Unknown Indication |
10.8% |
| Mycosis Fungoides |
6.4% |
| Psoriatic Arthropathy |
4.8% |
| Pain |
1.6% |
| Polymyalgia Rheumatica |
1.3% |
| Ankylosing Spondylitis |
1.0% |
| Chronic Obstructive Pulmonary Disease |
1.0% |
| Hypertension |
1.0% |
| Acute Lymphocytic Leukaemia |
0.6% |
| Benign Prostatic Hyperplasia |
0.6% |
| Deep Vein Thrombosis |
0.6% |
| Polyarthritis |
0.6% |
| Pustular Psoriasis |
0.6% |
| Thrombosis Prophylaxis |
0.6% |
| Analgesic Therapy |
0.3% |
| Arthritis |
0.3% |
| Atrial Fibrillation |
0.3% |
| Bacterial Infection |
0.3% |
|
| Saliva Altered |
11.4% |
| Impaired Healing |
9.1% |
| Mouth Ulceration |
6.8% |
| Pneumonia |
6.8% |
| Renal Impairment |
6.8% |
| Bronchial Carcinoma |
4.5% |
| Chest Pain |
4.5% |
| Chronic Obstructive Pulmonary Disease |
4.5% |
| Dermal Cyst |
4.5% |
| Facial Asymmetry |
4.5% |
| Hepatic Enzyme Increased |
4.5% |
| Ischaemia |
4.5% |
| Off Label Use |
4.5% |
| Pertussis |
4.5% |
| Pulmonary Fibrosis |
4.5% |
| Thrombocytopenia |
4.5% |
| Agranulocytosis |
2.3% |
| Anaemia Of Chronic Disease |
2.3% |
| Bursitis |
2.3% |
| Circulatory Collapse |
2.3% |
|
| Concomitant |
| Rheumatoid Arthritis |
33.3% |
| Product Used For Unknown Indication |
26.8% |
| Drug Use For Unknown Indication |
10.8% |
| Psoriatic Arthropathy |
3.5% |
| Prophylaxis |
2.8% |
| Hypertension |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Osteoporosis |
2.0% |
| Bone Marrow Conditioning Regimen |
1.9% |
| Pain |
1.6% |
| Acute Lymphocytic Leukaemia |
1.5% |
| B-cell Lymphoma |
1.5% |
| Crohn's Disease |
1.5% |
| Primary Mediastinal Large B-cell Lymphoma |
1.5% |
| Diabetes Mellitus |
1.3% |
| Histiocytosis Haematophagic |
1.3% |
| Infection Prophylaxis |
1.1% |
| Ankylosing Spondylitis |
1.0% |
| Juvenile Arthritis |
1.0% |
| Psoriasis |
0.9% |
|
| Sepsis |
8.9% |
| Activities Of Daily Living Impaired |
7.6% |
| Gamma-glutamyltransferase Increased |
7.6% |
| Vomiting |
7.6% |
| Postoperative Heterotopic Calcification |
6.3% |
| Acute Graft Versus Host Disease In Skin |
5.1% |
| Foot Operation |
5.1% |
| Respiratory Failure |
5.1% |
| Thrombocytopenia |
5.1% |
| Abortion |
3.8% |
| Bacteraemia |
3.8% |
| Chest Pain |
3.8% |
| Death |
3.8% |
| Hypotension |
3.8% |
| Lymphadenopathy |
3.8% |
| Pain In Extremity |
3.8% |
| Pyothorax |
3.8% |
| Renal Colic |
3.8% |
| Unresponsive To Stimuli |
3.8% |
| Urinary Tract Infection |
3.8% |
|
| Interacting |
| B-cell Lymphoma |
14.8% |
| Constipation |
11.1% |
| Drug Toxicity Prophylaxis |
11.1% |
| Drug Use For Unknown Indication |
7.4% |
| Hypertension |
7.4% |
| Rheumatoid Arthritis |
7.4% |
| Abdominal Discomfort |
3.7% |
| Antibiotic Therapy |
3.7% |
| Antiviral Prophylaxis |
3.7% |
| Chills |
3.7% |
| Diabetes Mellitus |
3.7% |
| Gastric Ph Decreased |
3.7% |
| Gout |
3.7% |
| Pain |
3.7% |
| Pyrexia |
3.7% |
| Respiratory Tract Infection |
3.7% |
| Vitamin Supplementation |
3.7% |
|
| Drug Interaction |
40.0% |
| Oesophageal Candidiasis |
20.0% |
| Skin Necrosis |
20.0% |
| Thrombocytopenia |
20.0% |
|
